We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Novo-N.Dkk1'b' | LSE:NVOB | London | Ordinary Share | DK0060102614 | DKK1 SER'B' |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.00 | - |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Transaction in Own Shares Novo Nordisk A/S - Share repurchase programme On 15 August 2008 Novo Nordisk initiated its share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules. Under the programme Novo Nordisk will repurchase B shares for an amount of up to DKK 1.7 billion in the period from 15 August 2008 to 19 December 2008. Since the announcement as of 17 November 2008, the following transactions have been made under the programme: Number of Average Transaction shares purchase price value, DKK Accumulated, last announcement 3,626,500 1,032,250,004 17 November 2008 50,000 295.7000 14,785,000 18 November 2008 50,000 287.9700 14,398,500 19 November 2008 50,000 284.8000 14,240,000 20 November 2008 75,000 287.2300 21,542,250 21 November 2008 100,000 275.1500 27,515,000 Accumulated under the programme 3,951,500 1,124,730,754 With the transactions stated above, Novo Nordisk owns a total of 24,918,285 treasury shares, corresponding to 3.9% of the share capital. The total amount of shares in the company is 634,000,000 including treasury shares. Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 26,550 employees in 80 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit novonordisk.com. Further information: Media: Investors: Outside North America Mads Veggerby Lausten Elin K Hansen Tel: (+45) 4443 7919 Tel: (+45) 4442 3450 mlau@novonordisk.com ekh@novonordisk.com Hans Rommer In North America: Tel: (+45) 4442 4765 Sean Clements hrmm@novonordisk.com Tel: (+1) 609 514 8316 secl@novonordisk.com Kasper Roseeuw Poulsen Tel: (+45) 4442 4471 krop@novonordisk.com Company Announcement no 77 / 2008 http://hugin.info/2013/R/1272517/282513.pdf This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
1 Year Novo-N.Dkk1'b' Chart |
1 Month Novo-N.Dkk1'b' Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions